Summary
RDY Chart
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Ltd. Dividends
 RDY In 1 month Estimated | Annual | $0.1 Per Share |
| RDY 10 months ago Paid | Annual | $0.1 Per Share |
| RDY 10 months ago | Annual | $0.48 Per Share |
| RDY 28 Jul 2023 Paid | Annual | $0.1 Per Share |
| RDY 7 Jul 2023 | Annual | $0.1 Per Share |
| RDY 1 Aug 2022 Paid | Annual | $0.08 Per Share |
Dr. Reddy's Laboratories Ltd. Earnings
| 28 Jan 2025 Date | | 16.15 Cons. EPS | 16.94 EPS |
| 25 Oct 2024 Date | | 0.98 Cons. EPS | 0.18 EPS |
| 27 Jul 2024 Date | | 78.22 Cons. EPS | 83.46 EPS |
| 24 Jul 2024 Date | | 0.91 Cons. EPS | - EPS |
| 7 May 2024 Date | | 68.45 Cons. EPS | 78.35 EPS |
| RDY In 1 month Estimated | Annual | $0.1 Per Share |
| RDY 10 months ago Paid | Annual | $0.1 Per Share |
| RDY 10 months ago | Annual | $0.48 Per Share |
| RDY 28 Jul 2023 Paid | Annual | $0.1 Per Share |
| RDY 7 Jul 2023 | Annual | $0.1 Per Share |
| RDY 1 Aug 2022 Paid | Annual | $0.08 Per Share |
| 28 Jan 2025 Date | | 16.15 Cons. EPS | 16.94 EPS |
| 25 Oct 2024 Date | | 0.98 Cons. EPS | 0.18 EPS |
| 27 Jul 2024 Date | | 78.22 Cons. EPS | 83.46 EPS |
| 24 Jul 2024 Date | | 0.91 Cons. EPS | - EPS |
| 7 May 2024 Date | | 68.45 Cons. EPS | 78.35 EPS |
Dr. Reddy's Laboratories Ltd. (RDY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dr. Reddy's Laboratories Ltd. ever had a stock split?
Dr. Reddy's Laboratories Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Erez Israeli M.B.A. CEO | NYSE Exchange | 256135203 Cusip |
| IN Country | 27,048 Employees | 30 Jul 2024 Last Dividend | 7 Sep 2006 Last Split | 11 Apr 2001 IPO Date |
Overview
Dr. Reddy's Laboratories Limited represents a multifaceted pharmaceutical entity with a global footprint, engaging in an integrated range of pharmaceutical activities. Established in 1984 and based in Hyderabad, India, the company maintains a broad operation spectrum through its distinct segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. These segments underline the company's diversified approach, encompassing the production and marketing of generic and branded pharmaceutical products, active pharmaceutical ingredients (APIs), and contract research services, along with a focused effort on developing therapies in oncology and inflammation. Their commitment to innovation and quality places them among the leading pharmaceutical companies worldwide.
Products and Services
- Global Generics
This segment is pivotal in manufacturing and marketing prescription and over-the-counter pharmaceutical products, available both under brand names and as generic formulations equivalent to branded counterparts. Dr. Reddy’s has made significant strides in the biologics domain under this segment, indicating a strong emphasis on advancing therapeutic solutions and accessibility.
- Pharmaceutical Services and Active Ingredients (PSAI)
A crucial arm of Dr. Reddy’s, the PSAI segment is responsible for the manufacturing and marketing of active pharmaceutical ingredients and intermediates – the essential components for finishing pharmaceutical products. Notably, it extends contract research services, catering to the diverse requirements of customers by providing custom synthesized APIs and steroids. This segment underscores the company’s role as a vital player in the pharmaceutical value chain, bolstering the global supply of key pharmaceutical ingredients.
- Others
Under this segment, Dr. Reddy's delineates its focus on the research and development department, particularly in crafting therapies for oncology and inflammation. Additionally, it embarks on the development of differentiated formulations aimed at enhancing therapeutic efficacy and patient compliance. Another noteworthy area within this segment is their investment in digital healthcare solutions and IT-enabled business support services, demonstrating a forward-looking approach to adapting in an increasingly digitalized healthcare landscape.
Contact Information
